FDA warned Wise Pharmacy that its compounded sterile and non-sterile drugs were adulterated by insanitary compounding conditions.
What happened
After a June 12–21, 2019 inspection, FDA issued a Form FDA 483 and found serious deficiencies in how the pharmacy made sterile and non-sterile drugs. FDA said the ISO 5 workstation for sterile compounding sat in a non-classified room with a sink and dishwasher, and cited cleaning, water-quality, airflow, and environmental-monitoring failures. The pharmacy recalled all sterile drugs within expiry on July 10, 2019 and stopped sterile compounding that day.
What FDA found
Sterile and non-sterile drugs were prepared under insanitary conditions that could contaminate them or make them harmful.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The ISO 5 workstation used for sterile drugs was located and operated in a non-classified room, and non-sterile drugs were compounded in that same room.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]A sink and dishwasher in the room with the ISO 5 workstation were potential sources of microbial contamination.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Cleaning practices for hoods handling hazardous and non-hazardous bulk drugs were deficient, so hazardous drugs were not adequately deactivated.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm did not confirm that water quality was suitable for making non-sterile drugs.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm lacked adequate dynamic smoke studies and its environmental monitoring was inadequate because samples were incubated at uncontrolled room temperature.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
What FDA wants
FDA tells the pharmacy to respond in writing within 15 working days describing corrective steps, and to notify FDA 15 days before resuming any sterile drug production. If it does not plan to resume sterile production, it may say so; FDA also recommends a third-party consultant with sterile manufacturing expertise before resuming.
Who should pay attention
- patient-safety and pharmacy quality teams
- health systems and clinics that buy compounded drugs
- compounding pharmacies and sterile-compounding operations
This is a summary. Read the original letter on fda.gov.